Signet raises $10M for oncology programs

By The Science Advisory Board staff writers

October 29, 2021 -- Signet Therapeutics has raised $10 million in a financing round led by 5Y Capital (Morningside Venture), with participation from Yael Capital, Blue Ocean Capital, and existing investors Tiantu Capital and Sky9 Capital.

The money will go toward advancing the company's two oncology programs to clinical trials. In addition, Signet said it plans to expand its platform of disease models to other cancer areas and enable target discovery and pharmacodynamics studies at other pharmaceutical companies on a greater scale.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.